Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
- PMID: 37793761
- DOI: 10.1016/S2352-3026(23)00278-8
Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
Conflict of interest statement
PR-O reports honoraria for lectures from, and membership of, advisory boards with Celgene-BMS, Janssen, Amgen, GSK, Oncopeptides, Sanofi, AbbVie, Roche, Regeneron, and Pfizer, and consultancy for Celgene, Janssen, Roche, Abbvie, Pfizer, and GSK. JFS-M reports institutional honoraria from, and consulting or advisory roles for Amgen, Celgene, Takeda, Bristol-Myers Squibb, MSD, Novartis, Sanofi, Janssen, Roche, and AbbVie. LET declares no conflict of interest.
Comment on
-
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0. Lancet Haematol. 2023. PMID: 37793771 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources